Suzhou Junjing Biosciences Co., Ltd.

This study tests a combination of two pills (WJ01024 and ruxolitinib) in about 33 adults with intermediate- or high-risk myelofibrosis whose spleen is enlarged and who didn't respond well to or couldn't tolerate previous JAK inhibitor treatment. The goal is to see if the combo is…